NIH Mobilizes National Innovation Initiative for COVID-19 Diagnostics

NIH Launches Public-Private Partnership to Speed COVID-19 Vaccine & Treatment Options

NIH and the Foundation for the NIH are bringing together biopharmaceutical companies, HHS partners, and the European Medicines Agency to develop a coordinated research response to the COVID-19 pandemic. The planned Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership will provide infrastructure, subject matter expertise, and/or funding to help move promising vaccine and drug candidates into clinical trials.

NIH Mobilizes National Innovation Initiative for COVID-19 Diagnostics

On April 29, NIH announced the Rapid Acceleration of Diagnostics Initiative (RADx), which aims to speed innovation, development, and commercialization of COVID-19 testing technologies. NIH, working closely with the US FDA, CDC, and the Biomedical Advanced Research and Development Authority, will put rapid testing technologies through a highly competitive, three-phase selection process to identify the best candidates for at-home or point-of-care tests for COVID-19. The goal is to make millions of accurate, easy-to-use tests per week available to all Americans by the end of summer 2020, and even more by flu season. NIH urges scientists and inventors working on rapid testing technology to compete in the national challenge for a share of up to $500 million over all phases of development.